Back to news

SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering

Globe Newswire•17/11/2026•16:01 ET
0

Key Highlights

  • ➤SELLAS (SLS) launches proposed $150.0 million underwritten public offering
  • ➤Underwriters receive 30-day option for up to an additional $22.5 million
  • ➤Offering remains subject to market conditions, with size and terms not guaranteed
  • ➤J.P. Morgan and TD Cowen serve as joint book-running managers

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions. All of the shares in the offering will be sold by SELLAS. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan and TD Cowen are acting as the joint book-running managers for the offering.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in